8-K: Iridex Reports Q1 2026 Results, Affirms Guidance

Iridex Corporation announced its first quarter 2026 financial results, reporting $11.8 million in revenue and reaffirming its full-year 2026 guidance.

Summary

• Iridex Corporation reported first quarter 2026 revenue of $11.8 million, a slight decrease of 1% from $11.9 million in the prior year period.
• Revenue was impacted by a decrease in retina product sales ($5.8 million vs. $6.6 million), partially offset by growth in Cyclo G6 product family revenue ($3.6 million, up 14%) and service/other revenues.
• Gross profit was $4.7 million (40% gross margin), down from $5.0 million (43% gross margin) in Q1 2025, attributed to higher manufacturing and product costs.
• Operating expenses decreased by 4% to $5.1 million, driven by lower consulting and legal expenses.
• The company reported a net loss of $0.5 million ($0.03 per share) for Q1 2026, an improvement from a net loss of $1.7 million ($0.10 per share) in the prior year period.
• Non-GAAP adjusted EBITDA was $0.3 million, compared to $0.4 million in Q1 2025.
• Cash and cash equivalents decreased to $4.6 million as of April 4, 2026, a planned usage for the quarter.
• Full-year 2026 revenue guidance remains between $51 million and $53 million, with expected positive operating cash flow.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, with results meeting expectations and guidance reaffirmed, but offset by revenue decline in a key segment and ongoing supply chain/regulatory delays.

Positives

• Cyclo G6 product family revenue grew 14% year-over-year to $3.6 million.
• 15,500 Cyclo G6 probes were sold, an increase from 13,900 in the prior year.
• Operating expenses were reduced by 4% compared to the prior year period.
• Net loss improved to $0.5 million from $1.7 million in the prior year quarter.
• The company expects to generate positive cash flow for the full fiscal year 2026.
• Full-year 2026 revenue guidance of $51 million to $53 million was reaffirmed.

Negatives

• Total revenue decreased by 1% to $11.8 million compared to $11.9 million in the prior year.
• Retina product revenue decreased to $5.8 million from $6.6 million in the prior year.
• Gross margin decreased to 40% from 43% due to higher manufacturing and product costs.
• Cash and cash equivalents decreased by $1.4 million during the quarter, ending at $4.6 million.

Risks

• International supply constraints impacted retina product revenue.
• Delayed regulatory approvals affected retina product revenue.
• Market disruptions from the conflict in the Middle East are impacting product delivery timelines.
• The company is transitioning to lower-cost contract manufacturers, which may involve initial cost increases.
• Forward-looking statements are subject to risks and uncertainties as detailed in the company's SEC filings.

Future Outlook

The company reaffirms its full-year 2026 revenue guidance of $51 million to $53 million, anticipating the impact of market disruptions. It also expects adjusted operating expenses between $19 million and $19.5 million and to generate positive operating cash flow for the full year.

Management Comments

• "Looking back at the first quarter of 2026, I am encouraged by our execution across the business as first quarter results were in line with our expectations, building the foundation for a cash flow positive fiscal year," said Patrick Mercer, President and CEO of Iridex.
• "Our U.S. glaucoma business delivered solid growth, and our cost structure improvements are flowing through as planned."
• "We remain confident in our ability to deliver on the priorities we've outlined: expanding G6 utilization, advancing regulatory approvals, and continuing to drive gross margin improvement."

Industry Context

StockSavvy.ai notes that Iridex Corporation, a leader in laser-based medical systems for ophthalmology, is navigating supply chain challenges and regulatory hurdles while focusing on growth in its glaucoma segment and cost management. The reaffirmation of guidance suggests confidence in its market position despite external pressures.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and improved net loss may be viewed positively, but revenue decline and cash burn in Q1 could be concerns.
• Employees: Cost structure improvements and focus on operational execution may indicate stability.
• Customers: Continued availability of Cyclo G6 products and potential for new regulatory approvals could benefit users.
• Suppliers: Transition to new contract manufacturers may impact existing supplier relationships.

Next Steps

• Continue to expand G6 utilization.
• Advance regulatory approvals.
• Drive gross margin improvement.
• Generate positive operating cash flow for fiscal year 2026.
• Improve quarterly cash generation sequentially for the remainder of the year.

Key Dates

Recommendation

The company met expectations for the quarter and reaffirmed guidance, showing resilience in its glaucoma segment and cost control. However, the revenue decline in retina products due to supply and regulatory issues, coupled with a decrease in cash reserves, warrants a cautious 'hold' until these challenges are fully resolved and growth in key areas is more robust.

Keywords

Iridex Corporation, IRIX, Glaucoma, Retinal Diseases, Medical Systems, Laser Technology, Ophthalmology, Financial Results